EPAS1 (Endothelial PAS domain protein 1)

News alerts, weekly reports and conference planners

Entrez ID:

EPAS1 overexpression	Glioblastoma	EPAS1 overexpression	Glioblastoma	bevacizumab + erlotinib Resistant: C3 – Early Trials bevacizumab + erlotinib Resistant : C3	bevacizumab + erlotinib Resistant: C3 – Early Trials bevacizumab + erlotinib Resistant : C3
EPAS1 overexpression	Clear Cell Renal Cell Carcinoma	EPAS1 overexpression	Clear Cell Renal Cell Carcinoma	pazopanib Resistant: C3 – Early Trials pazopanib Resistant : C3	pazopanib Resistant: C3 – Early Trials pazopanib Resistant : C3
TCF3-EPAS1 fusion	Acute Lymphocytic Leukemia	TCF3-EPAS1 fusion	Acute Lymphocytic Leukemia	MLN8237 Sensitive: D – Preclinical MLN8237 Sensitive : D	MLN8237 Sensitive: D – Preclinical MLN8237 Sensitive : D
EPAS1 overexpression	Hepatocellular Cancer	EPAS1 overexpression	Hepatocellular Cancer	sorafenib Resistant: D – Preclinical sorafenib Resistant : D	sorafenib Resistant: D – Preclinical sorafenib Resistant : D
EPAS1 G323E	Clear Cell Renal Cell Carcinoma	EPAS1 G323E	Clear Cell Renal Cell Carcinoma	belzutifan Sensitive: D – Preclinical belzutifan Sensitive : D	belzutifan Sensitive: D – Preclinical belzutifan Sensitive : D
EPAS1 S304M	Clear Cell Renal Cell Carcinoma	EPAS1 S304M	Clear Cell Renal Cell Carcinoma	belzutifan Sensitive: D – Preclinical belzutifan Sensitive : D	belzutifan Sensitive: D – Preclinical belzutifan Sensitive : D

Associations(6)